Aurinia Pharmaceuticals Inc.
AUPHHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Aurinia Pharmaceuticals Inc. (AUPH) is listed under Biotechnology. The company carries a $2.14B market cap, placing it firmly in the mid-cap category. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Market Cap
$2.14B
Beta
1.41
P/E (TTM)
7.05
P/E (Fwd)
15.07
EPS (TTM)
$2.28
EPS (Fwd)
$1.07
ROE
66.1%
ROA
15.5%
Cash
$443.0M
Total Debt
$64.1M
Free CF
$147.8M
52W Change
31.6%
Annual Financials
Cash vs Debt
Where AUPH stands vs its 150-day and 200-day moving averages
As of the August 21, 2026 close, AUPH finished 12.36% above its 150-day moving average ($15.37) and 12.14% above its 200-day moving average ($15.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AUPH overbought or oversold?
At the August 21, 2026 close, AUPH's RSI(14) was 72.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aurinia Pharmaceuticals Inc. holds $443.0M in cash against $64.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $147.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 66.1%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 15.5% further supports the picture of efficient asset utilization. Revenue has grown from $134.0M (2022) to $283.1M (2025), reflecting a 111% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Aurinia Pharmaceuticals Inc. and its sector.